Premier Biomedical Announces Therapeutic Advance in the Treatment and Prevention of Suicide and Depression

Dear Walter,

Researchers from Premier Biomedical were successful in removing the majority of target antigens associated with suicidal ideation and clinical depression from a heterogeneous mixture in a laboratory. This could be a major breakthrough against these two depressive disorder diseases. More on this story can be found at PR Newswire: <u>http://www.prnewswire.com/news-releases/premier-biomedical-announces-therapeuticadvance-in-the-treatment-and-prevention-of-suicide-and-depression-183925871.html</u>

For additional information about Premier Biomedical, Inc., including past press releases and coverage, please visit our website at: <u>www.premierbiomedical.com</u> or <u>www.premierbiomedical.com/newsroom</u>

If, after reviewing these materials, you have further questions and/or would like to interview CEO William A. Hartman or Chairman of the Scientific Advisory Board Dr. Mitchell S. Felder, please get back in touch with me and I will make the necessary arrangements.

I appreciate your interest in Premier Biomedical, Inc., and look forward to continuing our dialogue into the future. Thank you.

Regards, Justin A. Felder